company background image
ARCT

Arcturus Therapeutics Holdings NasdaqGM:ARCT Stock Report

Last Price

US$16.05

Market Cap

US$426.6m

7D

14.8%

1Y

-62.8%

Updated

06 Oct, 2022

Data

Company Financials +
ARCT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ARCT Stock Overview

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States.

Arcturus Therapeutics Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arcturus Therapeutics Holdings
Historical stock prices
Current Share PriceUS$16.05
52 Week HighUS$48.75
52 Week LowUS$11.70
Beta2.57
1 Month Change16.73%
3 Month Change-15.79%
1 Year Change-62.80%
3 Year Change53.15%
5 Year Changen/a
Change since IPO60.34%

Recent News & Updates

Sep 23
Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Aug 31

Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine

Arcturus Therapeutics (NASDAQ:ARCT) said on Wednesday it had obtained an award for up to $63.2M from the Biomedical Advanced Research and Development Authority. (ARCT) rose ~6% after the bell. The award will be provided over three years to support preclinical, manufacturing, nonclinical safety studies, along with development and regulatory support for Arcturus’ mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 clinical studies. Arcturus’ mRNA platform has been administered to over 10,000 individuals. The project has been supported in whole or in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority.

Aug 15
Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders will have a reason to smile today, with the analysts...

Shareholder Returns

ARCTUS BiotechsUS Market
7D14.8%2.4%3.3%
1Y-62.8%-21.0%-20.4%

Return vs Industry: ARCT underperformed the US Biotechs industry which returned -19.3% over the past year.

Return vs Market: ARCT underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is ARCT's price volatile compared to industry and market?
ARCT volatility
ARCT Average Weekly Movement13.7%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: ARCT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: ARCT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013177Joe Paynehttps://arcturusrx.com

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company’s development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis.

Arcturus Therapeutics Holdings Fundamentals Summary

How do Arcturus Therapeutics Holdings's earnings and revenue compare to its market cap?
ARCT fundamental statistics
Market CapUS$426.55m
Earnings (TTM)-US$165.48m
Revenue (TTM)US$40.57m

10.5x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ARCT income statement (TTM)
RevenueUS$40.57m
Cost of Revenue-US$12.65m
Gross ProfitUS$53.22m
Other ExpensesUS$218.69m
Earnings-US$165.48m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-6.23
Gross Margin131.17%
Net Profit Margin-407.91%
Debt/Equity Ratio36.8%

How did ARCT perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ARCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARCT?

Other financial metrics that can be useful for relative valuation.

ARCT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6x
Enterprise Value/EBITDA-1.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ARCT's PS Ratio compare to its peers?

ARCT PS Ratio vs Peers
The above table shows the PS ratio for ARCT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average13x
PRE Prenetics Global
1.4x15.8%US$401.7m
CCCC C4 Therapeutics
8.3x36.0%US$413.8m
FHTX Foghorn Therapeutics
38.3x47.7%US$351.0m
PGEN Precigen
4.1x17.2%US$428.8m
ARCT Arcturus Therapeutics Holdings
10.5x57.1%US$426.6m

Price-To-Sales vs Peers: ARCT is good value based on its Price-To-Sales Ratio (10.5x) compared to the peer average (13x).


Price to Earnings Ratio vs Industry

How does ARCT's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: ARCT is good value based on its Price-To-Sales Ratio (10.5x) compared to the US Biotechs industry average (14x)


Price to Sales Ratio vs Fair Ratio

What is ARCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARCT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.5x
Fair PS Ratio58.6x

Price-To-Sales vs Fair Ratio: ARCT is good value based on its Price-To-Sales Ratio (10.5x) compared to the estimated Fair Price-To-Sales Ratio (58.6x).


Share Price vs Fair Value

What is the Fair Price of ARCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ARCT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ARCT's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Arcturus Therapeutics Holdings forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


71.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARCT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: ARCT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ARCT is expected to become profitable in the next 3 years.

Revenue vs Market: ARCT's revenue (57.1% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: ARCT's revenue (57.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ARCT is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Arcturus Therapeutics Holdings performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-61.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ARCT is currently unprofitable.

Growing Profit Margin: ARCT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ARCT is unprofitable, and losses have increased over the past 5 years at a rate of 61.1% per year.

Accelerating Growth: Unable to compare ARCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ARCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: ARCT has a negative Return on Equity (-96.93%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Arcturus Therapeutics Holdings's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ARCT's short term assets ($291.5M) exceed its short term liabilities ($92.7M).

Long Term Liabilities: ARCT's short term assets ($291.5M) exceed its long term liabilities ($73.6M).


Debt to Equity History and Analysis

Debt Level: ARCT has more cash than its total debt.

Reducing Debt: ARCT's debt to equity ratio has increased from 0.4% to 36.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ARCT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ARCT has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 62.2% each year.


Discover healthy companies

Dividend

What is Arcturus Therapeutics Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Arcturus Therapeutics Holdings Dividend Yield vs Market
How does Arcturus Therapeutics Holdings dividend yield compare to the market?
SegmentDividend Yield
Company (Arcturus Therapeutics Holdings)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Arcturus Therapeutics Holdings)0%

Notable Dividend: Unable to evaluate ARCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ARCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ARCT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ARCT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ARCT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Joe Payne (50 yo)

9.58yrs

Tenure

US$960,000

Compensation

Mr. Joseph E. Payne, also known as Joe, M.Sc., has been Independent Non-Executive Director of Vallon Pharmaceuticals, Inc. since June 22, 2018. Mr. Payne has been Director of Arcturus since November 2017....


CEO Compensation Analysis

Joe Payne's Compensation vs Arcturus Therapeutics Holdings Earnings
How has Joe Payne's remuneration changed compared to Arcturus Therapeutics Holdings's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$165m

Mar 31 2022n/an/a

-US$198m

Dec 31 2021US$960kUS$600k

-US$204m

Sep 30 2021n/an/a

-US$196m

Jun 30 2021n/an/a

-US$163m

Mar 31 2021n/an/a

-US$119m

Dec 31 2020US$13mUS$500k

-US$72m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$38m

Mar 31 2020n/an/a

-US$29m

Dec 31 2019US$1mUS$450k

-US$26m

Sep 30 2019n/an/a

-US$16m

Jun 30 2019n/an/a

-US$13m

Mar 31 2019n/an/a

-US$22m

Dec 31 2018US$3mUS$425k

-US$22m

Sep 30 2018n/an/a

-US$26m

Jun 30 2018n/an/a

-US$25m

Mar 31 2018n/an/a

-US$16m

Dec 31 2017US$449kUS$384k

-US$11m

Compensation vs Market: Joe's total compensation ($USD960.00K) is below average for companies of similar size in the US market ($USD2.83M).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ARCT's management team is considered experienced (4.1 years average tenure).


Board Members

Experienced Board: ARCT's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqGM:ARCT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
25 Oct 21SellUS$8,904,000Ultragenyx Pharmaceutical Inc.Company200,000US$44.52

Ownership Breakdown

What is the ownership structure of ARCT?
Owner TypeNumber of SharesOwnership Percentage
Public Companies1,200,0004.5%
General Public2,004,0187.5%
Individual Insiders2,467,1339.3%
Institutions20,905,20678.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 81.63% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.4%
Federated Hermes, Inc.
3,561,097$57.2m-5.34%0.16%
10.56%
State Street Global Advisors, Inc.
2,806,918$45.1m-12.77%no data
8.67%
ARK Investment Management LLC
2,303,751$37.0m-3.36%0.23%
7.17%
BlackRock, Inc.
1,904,302$30.6m12.31%no data
5.55%
Joseph Payne
1,475,097$23.7m0%no data
5.4%
Nikko Asset Management Co., Ltd.
1,436,194$23.1m2.43%0.01%
4.52%
Ultragenyx Pharmaceutical Inc.
1,200,000$19.3m0%no data
4.49%
The Vanguard Group, Inc.
1,193,656$19.2m3.48%no data
3.61%
Point72 Asset Management, L.P.
959,565$15.4m122.84%0.04%
3.46%
FMR LLC
920,757$14.8m0%no data
2.24%
Padmanabh Chivukula
594,448$9.5m0%no data
1.48%
Geode Capital Management, LLC
392,537$6.3m5.81%no data
1.17%
Goldman Sachs Group, Investment Banking and Securities Investments
311,640$5.0m22.33%no data
1.17%
J.P. Morgan Asset Management, Inc.
311,544$5.0m-0.18%no data
1.16%
Morgan Stanley, Investment Banking and Brokerage Investments
308,443$5.0m10.39%no data
1.01%
Andrew Sassine
269,303$4.3m-1.44%no data
1.01%
Schonfeld Strategic Advisors LLC
267,597$4.3m251.66%0.04%
0.85%
ACT Capital Management
226,600$3.6m-10.54%4.76%
0.79%
Northern Trust Global Investments
208,896$3.4m7.84%no data
0.77%
Millennium Management LLC
204,596$3.3m0%no data
0.75%
Rafferty Asset Management, LLC
200,186$3.2m-33.75%0.03%
0.66%
Wells Fargo & Company, Securities and Brokerage Investments
175,539$2.8m14.08%no data
0.59%
Integral Health Asset Management, LLC
156,553$2.5m25.24%0.44%
0.59%
Charles Schwab Investment Management, Inc.
156,258$2.5m1.1%no data
0.56%
Dimensional Fund Advisors LP
149,392$2.4m-31.34%no data

Company Information

Arcturus Therapeutics Holdings Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Arcturus Therapeutics Holdings Inc.
  • Ticker: ARCT
  • Exchange: NasdaqGM
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$426.551m
  • Shares outstanding: 26.58m
  • Website: https://arcturusrx.com

Number of Employees


Location

  • Arcturus Therapeutics Holdings Inc.
  • 10628 Science Center Drive
  • Suite 250
  • San Diego
  • California
  • 92121
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ARCTNasdaqGM (Nasdaq Global Market)YesNew Ordinary SharesUSUSDNov 2017

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/06 00:00
End of Day Share Price2022/10/06 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.